MedTrace Logo

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

NCT03376763 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2021-12-17

No results posted yet for this study

Summary

Interventional, multicenter, open-label, 20 weeks study

* To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.
* To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena

Conditions

  • Schizophrenia
  • Antipsychotics
  • Long-Acting Injection
  • LAI
  • Aripiprazole

Interventions

DRUG

Abilify maintena

Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jun Soo Kwon, Dr. · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-21
Primary Completion
2021-11-19
Completion
2021-11-19

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03376763 on ClinicalTrials.gov